Androgen Receptor mRNA Expression is Positively Associated With Live Birth in Women Undergoing IVF Independently of the Type of Ovarian Response

Androgen Receptor (AR) mRNA Expression is Positively Associated With Live Birth in Women Undergoing In-vitro Fertilization Independently of the Type of Ovarian Response

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03433768

Enrollment

Registered

2018-02-15

Start date

2014-09-14

Completion date

2018-01-10

Last updated

2018-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Androgen Receptor Gene Overexpression, Bologna Criteria, Normal Responders, Poor Ovarian Response

Brief summary

AR is a steroid hormone receptor that regulates various genes' expression and affects cellular proliferation and differentiation. Androgens interact with AR, exert their paracrine action on granulosa cells and regulate gonadotropin synthesis, follicle development, oocyte maturation and corpus luteum function. Estrogens increase AR mRNA and testosterone binding site in uterine endometrium and leiomyoma. In human cancer cells, low estradiol increases AR levels, suggesting the estrogen/androgen ratio as a predictor of sex steroid response. AR mRNA expression is, also, regulated by progesterone. Although AR mRNA is expressed in the female reproductive tissues, its expression has never been studied in peripheral blood.

Interventions

GENETICReal time PCR

We take peripheral blood sample at day one, six and ten of ovarian stimulation and measure mRNA expression of androgen receptor.

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 42 Years

Inclusion criteria

* Women with poor ovarian response according to bologna criteria 1. Advanced maternal age (≥40 years) or any other risk factor for poor ovarian response 2. A previous poor ovarian response (≤3 oocytes with a conventional stimulation protocol) 3. Abnormal ovarian reserve test, (AFC ˂5-7 follicles or AMH ˂0.5-1.1 ng/ml). * Women with normal ovarian response with normal menstrual cycles, normal astral follicle count and normal hormonal assay.

Exclusion criteria

* Not more than 43 years old. * No history of malignancies, endometriosis or polycystic ovary syndrome. * Underlying genetic cause of infertility * History of severe cardiac, hepatic or renal disease. * History of systemic disease or treatment during the last three (3) months * Participation in another interventional study and a likelihood of being unavailable for follow-up.

Design outcomes

Primary

Measure	Time frame	Description
Androgen Receptor mRNA expression	day one, six and ten of ovarian stimulation	The expression of androgen receptor mRNA in peripheral blood of normal and poor responders level of expression in peripheral blood according to the Delta-Delta-Ct (ddCt) Algorithm. Percentage of increase?

Secondary

Measure	Time frame	Description
Serum LH levels in peripheral blood of normal and poor responders	day one, six and ten of ovarian stimulation	level of hormone in international unit.
Serum progesterone levels in peripheral blood of normal and poor responders.	day one, six and ten of ovarian stimulation	level of hormone in international unit.
Serum estradiol levels in peripheral blood of normal and poor responders	day one, six and ten of ovarian stimulation	level of hormone in international unit.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026